EVGN
Price
$1.31
Change
-$0.04 (-2.96%)
Updated
Jul 25 closing price
Capitalization
11.63M
10 days until earnings call
RARE
Price
$27.34
Change
+$0.04 (+0.15%)
Updated
Jul 25 closing price
Capitalization
2.58B
4 days until earnings call
Interact to see
Advertisement

EVGN vs RARE

Header iconEVGN vs RARE Comparison
Open Charts EVGN vs RAREBanner chart's image
Evogene
Price$1.31
Change-$0.04 (-2.96%)
Volume$68.85K
Capitalization11.63M
Ultragenyx Pharmaceutical
Price$27.34
Change+$0.04 (+0.15%)
Volume$1.25M
Capitalization2.58B
EVGN vs RARE Comparison Chart in %
Loading...
EVGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EVGN vs. RARE commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVGN is a Hold and RARE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (EVGN: $1.31 vs. RARE: $27.34)
Brand notoriety: EVGN and RARE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EVGN: 3% vs. RARE: 63%
Market capitalization -- EVGN: $11.63M vs. RARE: $2.58B
EVGN [@Biotechnology] is valued at $11.63M. RARE’s [@Biotechnology] market capitalization is $2.58B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVGN’s FA Score shows that 0 FA rating(s) are green whileRARE’s FA Score has 0 green FA rating(s).

  • EVGN’s FA Score: 0 green, 5 red.
  • RARE’s FA Score: 0 green, 5 red.
According to our system of comparison, EVGN is a better buy in the long-term than RARE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVGN’s TA Score shows that 2 TA indicator(s) are bullish while RARE’s TA Score has 4 bullish TA indicator(s).

  • EVGN’s TA Score: 2 bullish, 6 bearish.
  • RARE’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, RARE is a better buy in the short-term than EVGN.

Price Growth

EVGN (@Biotechnology) experienced а -0.76% price change this week, while RARE (@Biotechnology) price change was +3.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

EVGN is expected to report earnings on Aug 06, 2025.

RARE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RARE($2.59B) has a higher market cap than EVGN($11.6M). EVGN YTD gains are higher at: -29.947 vs. RARE (-35.013). EVGN has higher annual earnings (EBITDA): -14.42M vs. RARE (-449.9M). RARE has more cash in the bank: 494M vs. EVGN (9.85M). EVGN has less debt than RARE: EVGN (13M) vs RARE (38.3M). RARE has higher revenues than EVGN: RARE (591M) vs EVGN (6.77M).
EVGNRAREEVGN / RARE
Capitalization11.6M2.59B0%
EBITDA-14.42M-449.9M3%
Gain YTD-29.947-35.01386%
P/E Ratio0.30N/A-
Revenue6.77M591M1%
Total Cash9.85M494M2%
Total Debt13M38.3M34%
FUNDAMENTALS RATINGS
EVGN vs RARE: Fundamental Ratings
EVGN
RARE
OUTLOOK RATING
1..100
655
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6493
P/E GROWTH RATING
1..100
90100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EVGN's Valuation (35) in the Biotechnology industry is somewhat better than the same rating for RARE (74). This means that EVGN’s stock grew somewhat faster than RARE’s over the last 12 months.

EVGN's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that EVGN’s stock grew similarly to RARE’s over the last 12 months.

EVGN's SMR Rating (100) in the Biotechnology industry is in the same range as RARE (100). This means that EVGN’s stock grew similarly to RARE’s over the last 12 months.

EVGN's Price Growth Rating (64) in the Biotechnology industry is in the same range as RARE (93). This means that EVGN’s stock grew similarly to RARE’s over the last 12 months.

EVGN's P/E Growth Rating (90) in the Biotechnology industry is in the same range as RARE (100). This means that EVGN’s stock grew similarly to RARE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVGNRARE
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
72%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
78%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
79%
Bullish Trend 5 days ago
77%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 13 days ago
80%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
85%
Aroon
ODDS (%)
Bearish Trend 3 days ago
88%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
EVGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RARE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IJSSX13.960.10
+0.72%
VY® JPMorgan Small Cap Core Equity S
JGRJX40.190.20
+0.50%
JPMorgan Growth Advantage R2
PJDAX18.450.06
+0.33%
PGIM Jennison Rising Dividend A
SZCRX52.860.05
+0.09%
DWS Small Cap Core R6
TCREX18.02-0.01
-0.06%
Nuveen Real Estate Sec Sel A

EVGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVGN has been loosely correlated with CARM. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if EVGN jumps, then CARM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVGN
1D Price
Change %
EVGN100%
-2.96%
CARM - EVGN
59%
Loosely correlated
-1.62%
INSM - EVGN
32%
Poorly correlated
+0.42%
PMVP - EVGN
29%
Poorly correlated
-2.08%
ABOS - EVGN
26%
Poorly correlated
N/A
RARE - EVGN
25%
Poorly correlated
+0.15%
More

RARE and

Correlation & Price change

A.I.dvisor indicates that over the last year, RARE has been loosely correlated with MREO. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if RARE jumps, then MREO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RARE
1D Price
Change %
RARE100%
+0.15%
MREO - RARE
66%
Loosely correlated
+1.15%
SNDX - RARE
48%
Loosely correlated
-3.60%
IMVT - RARE
46%
Loosely correlated
-7.48%
NRIX - RARE
46%
Loosely correlated
-0.09%
REPL - RARE
46%
Loosely correlated
+1.61%
More